On 3 March 2026, the 22nd European LeukemiaNet (ELN) Symposium was held in Mannheim, Germany — one of the key international events in the field of hematology. The event brought together leading experts to discuss a wide range of topics, from molecular biology and genomics to the implementation of new therapeutic strategies and artificial intelligence methods in clinical practice.
A delegation from the NMRC for Hematology of the Russian Ministry of Health took part in the symposium. During the session dedicated to new approaches to the treatment of acute myeloid leukemia (AML), Candidate of Medical Sciences Anastasia Kashlakova, presented preliminary results from the Russian clinical protocol IMPACT-AML. The study aims to identify optimal treatment strategies for patients with relapsed and refractory acute myeloid leukemia (R/R AML).
Doctor of Medical Sciences Ekaterina Chelysheva, a member of the ELN working group on chronic myeloid leukemia (CML), actively participated in the symposium. During the specialized sessions, current standards of CML therapy, the improvement of international clinical recommendations, and issues of molecular monitoring of the disease were discussed.
Valeria Surimova, a specialist from the Information and Analytics Division and a participant in the working group of the Russian IMPACT-AML protocol, presented a poster on the use of machine learning methods for analyzing clinical and genetic data in hematology.
Participation in the 22nd ELN Symposium allowed Russian specialists to exchange experiences with leading international research groups, discuss current clinical trial results, and continue to foster international scientific collaboration.
